Download Monoclonal Antibodies table(2) updated November 2012

Monoclonal Antibodies - Unconjugated
Target
Agent (Brand)
Indications

Non-Hodgkin’s Lymphoma
Ofatumumab

Chronic lymphocytic leukemia (CLL) refractory to
fludarabine and alemtuzumab.
(Arzerra ®,
GlaxoSmithKline)

GSK's Arzerra website for providers
Alemtuzumab

Chronic lymphocytic leukemia (B-CLL
(Campath ®,
Genzyme)

Genzyme's Campath website for providers

Colorectal cancer: metastatic K-ras wildtype in
combination with FOLFIRI

squamous cell carncinoma of the head and neck
Rituximab
Rituxan ®,Genentech
CD-20
CD-52
Cetuximab
EGFR
Her-2
EGFR
(Erbitux ®, ImClone,
LLC)
o
with radiation therapy
o
after platinum therapy failure

ImClone's Erbitux website
Panitumumab

Colorectal cancer: metastatic, K-ras wildtype
(Vectibix ®, Amgen)

Amgen’s Vectibix website for providers

Breast cancer, HER2-overexpressing, adjuvant
setting:
o
with doxorubicin, cyclophosphamide, and
either paclitaxel or docetaxel
Trastuzumab
o
with docetaxel and carboplatin.
(Herceptin (R),
Genetech)
o
as a single agent following multi-modality
anthracycline-based therapy

Breast cancer, HER2-overexpressing, metastatic
setting:
o
first-line with paclitaxel
o
second or third line as a single agent

Pertuzumab
(Perjeta (R),
Genentech/Roche)
in combination with trastuzumab and docetaxel
for the treatment of patients with HER2-positive
metastatic breast cancer who have not received
prior anti-HER2 therapy or chemotherapy for
metastatic disease.
 Colorectal cancer: metastatic
 Non-squamous non-small cell lung cancer,
Bevacizumab
VEGF
(Avastin, ®,
Genentech)
 Breast cancer: Metastatic
 Glioblastoma, as a single agent for patients with
progressive disease following prior therapy.
 Metastatic renal cell carcinoma with interferon alfa
 http://www.NursingACE.com
Ipilimumab
CTLA-4
(Yervoy TM, Bristol
Meyers Squib))
 Unresectable or metastatic melanoma
 Links: BMS website for providers
Monoclonal Antibodies - Conjugated
Target
Agent (Brand)
Tositumomab &
Iodine I131
Indications
Follicular, non-Hodgkin’s lymphoma (NHL), resistant to
Rituximab and has relapsed following chemotherapy.
(Bexxar ®,
GlaxoSmithKline)
CD-20
CD-33
Ibritumomab &
tiuxetan Y-90)/In111
 Previously untreated follicular non-Hodgkin’s lymphoma
(NHL) who achieve a partial or complete response to
first-line chemotherapy
(Zevalin (R),
Spectrum
Pharmaceuticals)
 Relapsed or refractory, low-grade or follicular B-cell
NHL
Gemtuzumab
ozogamicin
(Mylotarg (R), Pfizer)
 Pfizer Inc. voluntarily withdrew the drug Mylotarg
(gemtuzumab ozogamicin) from the U.S. market for
patients with acute myeloid leukemia (AML). The
company took the action at the request of the U.S. Food
and Drug Administration after results from a recent
clinical trial raised new concerns about the product’s
safety and the drug failed to demonstrate clinical benefit
to patients enrolled in trials..
aflibercept injection
(ZALTRAP ®, Sanofi U.S., Inc)
“VEGF trap”
carfilzomib injection
(Kyprolis ®, Onyx
Pharmaceuticals),
Other mechanisms
Metastatic colorectal cancer (mCRC): in
combination with 5-fluorouracil, leucovorin,
irinotecan (FOLFIRI) for the treatment of patients
with metastatic colorectal cancer (mCRC) that is
resistant to or has progressed following an
oxaliplatin containing regimen
Multiple Myeloma: for patients have received at
least two prior therapies, including bortezomib and
an immunomodulatory agent, and have
demonstrated disease progression on or within 60
days of the completion of the last therapy.